Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles. Hall J et al. Thromb Res. 2016 Aug 17;146:20-22. doi: 10.1016/j.thromres.2016.08.017. [Epub ahead of print]. Diarrhea in Multiple Myeloma: A Review of the Literature. Faiman B et al. Clin J Oncol Nurs. 2016 Aug 1;20(4):E100-5. doi: 10.1188/16.CJON.E100-E105. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance. Castillo…Details
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Chakraborty R et al. Bone Marrow Transplant. 2016 Aug 22. doi: 10.1038/bmt.2016.214. [Epub ahead of print]. Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Kouroukis CT et al. Curr Oncol. 2016 Aug;23(4):e409-30. doi: 10.3747/co.23.3137. Epub 2016 Aug 12. Mobilization of autologous…Details
A revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement…Details
The International Myeloma Working Group (IMWG) has recently published further consensus criteria for defining disease response in myeloma. Since the original response criteria were set in 2006, newer, more sensitive methods can now quantify myeloma cells as low as 1 in a million. Published in the Lancet Oncology, the updated criteria identify responses beyond complete response…Details
Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis. Wei B et al. Onco Targets Ther. 2016 Jul 1;9:4015-22. doi: 10.2147/OTT.S102733. eCollection 2016. RGS1 expression is associated with poor prognosis in multiple myeloma. Roh J et al. J Clin Pathol. 2016 Jul 21. pii: jclinpath-2016-203713. doi: 10.1136/jclinpath-2016-203713. [Epub ahead of print]. Diagnostic performances of M-protein tests according to the clinical presentations…Details
Rationale, application, and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Merlini G et al. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.191. [Epub ahead of print]. Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Hogan JJ et al. Clin J Am Soc Nephrol. 2016 Jul 14. pii:…Details
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A et al. Cancer. 2016 Jul 19. doi: 10.1002/cncr.30174. [Epub ahead of print].
T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma.
Ali SA et al. Blood. 2016 Jul 13. pii: blood-2016-04-711903. [Epub ahead of print].
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Colombo M et al. Oncotarget. 2016 Jul 24. doi: 10.18632/oncotarget.10820. [Epub ahead of print]. HLA polymorphism and risk of multiple myeloma. Beksac M et al. Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Ito T et…Details
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Citrin R et al. Expert Rev Hematol. 2016 Jul 22. [Epub ahead of print]. A new era of immune therapy in multiple myeloma. Tai YT et al. Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden…Details
Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing.
Malhotra K et al. BMC Cancer. 2016 Jul 11;16:444. doi: 10.1186/s12885-016-2495-7.